Global Cord Blood (NYSE:CO) Receives New Coverage from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a research note issued to investors on Monday. The firm set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Trading Up 34.7 %

Shares of Global Cord Blood stock opened at $2.99 on Monday. The company has a fifty day simple moving average of $1.23 and a 200-day simple moving average of $1.35. Global Cord Blood has a 12-month low of $2.03 and a 12-month high of $5.50. The stock has a market cap of $363.44 million, a price-to-earnings ratio of 4.67 and a beta of 0.16.

About Global Cord Blood

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.